Key Takeaways:
Avalyn Pharma Inc. raised $300 million in an upsized initial public offering priced at $18.00 per share, providing significant capital to advance its pipeline of inhaled therapies for rare respiratory diseases. The offering was increased to 16,666,667 shares, a significant step-up from a target that aimed for around $200 million.
"By leveraging its proprietary drug-device approach and deep expertise in rare respiratory disease development, Avalyn aims to establish a new standard of care in pulmonary fibrosis through inhaled, lung-targeted therapies," the company stated in its press release.
The offering was increased to 16,666,667 shares, up from an initial target that would have raised approximately $200 million. Underwriters, including Morgan Stanley and Jefferies, hold a 30-day option to purchase an additional 2.5 million shares. Shares are set to begin trading on the Nasdaq on April 30 under the ticker AVLN.
The capital infusion is critical for Avalyn as it pushes two lead candidates through mid-stage clinical trials targeting pulmonary fibrosis, a market estimated to reach $5.8 billion by 2034. The company aims to challenge established treatments from Roche and Boehringer Ingelheim by offering what it calls a "more reliable and patient-friendly solution" with potentially fewer side effects.
Avalyn’s strategy centers on improving established antifibrotic medicines by changing their delivery method. The company’s lead program, AP01, is an inhaled version of pirfenidone (formerly sold as Esbriet) currently in a Phase 2b trial for progressive pulmonary fibrosis. Its second candidate, AP02, is an inhaled formulation of nintedanib (Ofev) in a Phase 2 study for idiopathic pulmonary fibrosis (IPF).
The company expects topline data from both trials by the end of 2027. Success in these programs would position Avalyn to compete in a market with significant unmet needs, as existing oral drugs have well-documented tolerability issues that limit their use. Avalyn is also developing AP03, a combination of both drugs, set to enter Phase 1 trials this year.
While Avalyn’s approach is promising, it faces a competitive field. An estimated 300,000 people in the U.S. have pulmonary fibrosis, and several companies are vying for a share of the market.
United Therapeutics is expected to seek approval for its drug Tyvaso in IPF later this year. Other major players with drugs in development include Bristol Myers Squibb and Contineum Therapeutics. The upsized IPO, the eighth for a biotech in 2026, reflects strong investor confidence in Avalyn's potential to capture a significant portion of this growing therapeutic area.
This article is for informational purposes only and does not constitute investment advice.
